Patients with mild cases of coronavirus disease 2019 (COVID-19) had cellular immunity after 6 months; political support among caregivers of patients with COVID-19 was spotlighted; 2 lots of type 2 diabetes (T2D) drug metformin recalled over possible contamination.
As reported by Reuters, a study from the United Kingdom examining a small patient cohort of 100 nonhospitalized patients with mild or asymptomatic coronavirus disease 2019 (COVID-19) found that cellular immunity to the virus remained present after 6 months, indicating that those infected may have some level of protection for at least that amount of time. Although scientists presenting the findings indicated that this discovery is reassuring, they note that people may still be prone to rare cases of being infected twice with COVID-19.
In an article by The New York Times, political support amongst caregivers of patients with COVID-19 was spotlighted. With almost 40% of all American COVID-19 deaths being linked to nursing homes and similar facilities, caregivers and frontline workers have been subject to rising fatalities as they provide support to older people at risk of isolation, distress, and mortality. In Pennsylvania, 1 of the country’s most important battleground states, caregivers described how their experiences are shaping their political support amidst the election, with some noting that faster, clearer, and better-coordinated government intervention could have saved lives.
CNN reports that 2 lots of the widely used type 2 diabetes (T2D) medication metformin were recalled over possible contamination with a potentially cancer-causing compound known as nitrosamine, or NDMA. The recall, which was posted by the FDA, occurred in Nostrum Laboratories Inc, based in Kansas City, Missouri, and involved metformin HCI extended release tablets, USP 750 mg. Considered a possible carcinogen by the Environmental Protection Agency, NDMA has been found in certain blood pressure drugs and antacids, with this case exhibiting levels of the compound that are above the acceptable limit.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen